BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Horisberger A, La Rosa S, Zurcher JP, Zimmermann S, Spertini F, Coukos G, Obeid M. A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. J Immunother Cancer 2018;6:156. [PMID: 30587227 DOI: 10.1186/s40425-018-0481-0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 10.7] [Reference Citation Analysis]
Number Citing Articles
1 Laino AS, Woods D, Vassallo M, Qian X, Tang H, Wind-Rotolo M, Weber J. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J Immunother Cancer 2020;8:e000842. [PMID: 32581042 DOI: 10.1136/jitc-2020-000842] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 26.0] [Reference Citation Analysis]
2 Morgado M, Plácido A, Morgado S, Roque F. Management of the Adverse Effects of Immune Checkpoint Inhibitors. Vaccines (Basel) 2020;8:E575. [PMID: 33019641 DOI: 10.3390/vaccines8040575] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Alhatem A, Patel K, Eriksen B, Bukhari S, Liu C. Nivolumab-Induced Concomitant Severe Upper and Lower Gastrointestinal Immune-Related Adverse Effects. ACG Case Rep J 2019;6:e00249. [PMID: 32309466 DOI: 10.14309/crj.0000000000000249] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Zhou L, Wei X. Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer. Front Immunol 2021;12:701951. [PMID: 34504488 DOI: 10.3389/fimmu.2021.701951] [Reference Citation Analysis]
5 Gerges Harb J, Noureldine HA, Chedid G, Eldine MN, Abdallah DA, Chedid NF, Nour-Eldine W. SARS, MERS and COVID-19: clinical manifestations and organ-system complications: a mini review. Pathog Dis 2020;78:ftaa033. [PMID: 32633327 DOI: 10.1093/femspd/ftaa033] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 22.0] [Reference Citation Analysis]
6 Bonomi M, Maltese M, Brighenti M, Muri M, Passalacqua R. Tocilizumab for COVID-19 Pneumonia in a Patient With Non-Small-cell Lung Cancer Treated With Chemoimmunotherapy. Clin Lung Cancer 2021;22:e67-9. [PMID: 32952047 DOI: 10.1016/j.cllc.2020.08.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Doms J, Prior JO, Peters S, Obeid M. Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis. Ann Oncol 2020;31:1273-5. [PMID: 32425357 DOI: 10.1016/j.annonc.2020.05.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
8 Hu W, Wang G, Wang Y, Riese MJ, You M. Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. iScience 2020;23:101580. [PMID: 33083746 DOI: 10.1016/j.isci.2020.101580] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
9 Bersanelli M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Immunotherapy. 2020;12:269-273. [PMID: 32212881 DOI: 10.2217/imt-2020-0067] [Cited by in Crossref: 121] [Cited by in F6Publishing: 119] [Article Influence: 121.0] [Reference Citation Analysis]
10 Cheung VTF, Brain O. Immunotherapy induced enterocolitis and gastritis - What to do and when? Best Pract Res Clin Gastroenterol 2020;48-49:101703. [PMID: 33317787 DOI: 10.1016/j.bpg.2020.101703] [Reference Citation Analysis]
11 Inoue G, Utsumi T, Yoshizawa A. Uncommon esophagitis associated with nivolumab and ipilimumab therapy. Dig Endosc 2021;33:467-8. [PMID: 33251627 DOI: 10.1111/den.13902] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Campochiaro C, Farina N, Tomelleri A, Ferrara R, Lazzari C, De Luca G, Alessandra B, Signorelli D, Palmisano A, Vignale D, Peretto G, Sala S, Esposito A, Garassino M, Gregorc V, Dagna L. Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. Eur J Intern Med 2021:S0953-6205(21)00266-1. [PMID: 34391591 DOI: 10.1016/j.ejim.2021.07.016] [Reference Citation Analysis]
13 Tanaka R, Ichimura Y, Kubota N, Saito A, Nakamura Y, Ishitsuka Y, Watanabe R, Fujisawa Y, Kanzaki M, Mizuno S, Takahashi S, Fujimoto M, Okiyama N. Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6. Commun Biol 2020;3:571. [PMID: 33060784 DOI: 10.1038/s42003-020-01308-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
14 Haanen J, Ernstoff MS, Wang Y, Menzies AM, Puzanov I, Grivas P, Larkin J, Peters S, Thompson JA, Obeid M. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Ann Oncol 2020;31:724-44. [PMID: 32194150 DOI: 10.1016/j.annonc.2020.03.285] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 37.0] [Reference Citation Analysis]
15 Yalcin AD, Yalcin AN. Future perspective: biologic agents in patients with severe COVID-19. Immunopharmacol Immunotoxicol 2021;43:1-7. [PMID: 32883116 DOI: 10.1080/08923973.2020.1818770] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
16 Sullivan RJ, Weber JS. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nat Rev Drug Discov 2021. [PMID: 34316029 DOI: 10.1038/s41573-021-00259-5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
17 Liu X, Shi X, Guo W, Ke Y, Li Y, Pan S, Li X, Liu M, Liu M, Wang Y, Ruan Q, Ma H. A Promising Esophageal Cancer Prognostic Signature of Ferroptosis-Related LncRNA to Predict Immune Scenery and Immunotherapy Response. Int J Gen Med 2021;14:5845-62. [PMID: 34566425 DOI: 10.2147/IJGM.S327555] [Reference Citation Analysis]
18 Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019;16:563-80. [PMID: 31092901 DOI: 10.1038/s41571-019-0218-0] [Cited by in Crossref: 343] [Cited by in F6Publishing: 349] [Article Influence: 171.5] [Reference Citation Analysis]
19 Kang JH, Bluestone JA, Young A. Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines. Trends Immunol 2021;42:293-311. [PMID: 33714688 DOI: 10.1016/j.it.2021.02.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
20 Moi L, Bouchaab H, Mederos N, Nguyen-Ngoc T, Perreau M, Fenwick C, Vaucher J, Sempoux C, Peters S, Obeid M. Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis. J Thorac Oncol 2021;16:318-26. [PMID: 32956849 DOI: 10.1016/j.jtho.2020.09.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
21 Ke W, Zhang L, Dai Y. The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs). Thorac Cancer 2020;11:835-9. [PMID: 32043828 DOI: 10.1111/1759-7714.13341] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
22 Haanen J, Ernstoff M, Wang Y, Menzies A, Puzanov I, Grivas P, Larkin J, Peters S, Thompson J, Obeid M. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. J Immunother Cancer 2020;8:e000604. [PMID: 32532839 DOI: 10.1136/jitc-2020-000604] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 26.0] [Reference Citation Analysis]
23 Douglas VP, Douglas KA, Cestari DM. Immune checkpoint inhibitors: what neuro-ophthalmologists need to know. Current Opinion in Ophthalmology 2019;30:426-33. [DOI: 10.1097/icu.0000000000000608] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]